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Mutational effects of human 
dopamine transporter at 
tyrosine88, lysine92, and 
histidine547 on basal and HIV-1  
Tat-inhibited dopamine transport
Wei-Lun sun1, Pamela M. Quizon1, Yaxia Yuan2,3, Matthew J. Strauss1, Richard McCain Jr.1, 
Chang-Guo Zhan2,3 & Jun Zhu1
Dysregulation of dopaminergic system induced by HIV-1 Tat protein-mediated direct inhibition 
of the dopamine transporter (DAT) has been implicated as a mediating factor of HIV-1 associated 
neurocognitive disorders. We have reported that single point mutations on human DAT (hDAT) at 
tyrosine88 (Y88F), lysine92 (K92M), and histidine547 (H547A) differentially regulate basal dopamine 
uptake but diminish Tat-induced inhibition of dopamine uptake by changing dopamine transport 
process. This study evaluated the effects of double (Y88F/H547A) and triple (Y88F/K92M/H547A) 
mutations on basal dopamine uptake, Tat-induced inhibition of DAT function, and dynamic transport 
process. Compared to wild-type hDAT, the Vmax values of [3H]Dopamine uptake were increased by 
96% in Y88F/H547A but decreased by 97% in Y88F/K92M/H547A. [3H]WIN35,428 binding sites were 
not altered in Y88F/H547A but decreased in Y88F/K92M/H547A. Y88F/H547A mutant attenuated 
Tat-induced inhibition of dopamine uptake observed in wild-type hDAT. Y88F/H547A displayed an 
attenuation of zinc-augmented [3H]WIN35,428 binding, increased basal dopamine efflux, and reduced 
amphetamine-induced dopamine efflux, indicating this mutant alters transporter conformational 
transitions. These findings further demonstrate that both tyrosine88 and histidine547 on hDAT 
play a key role in stabilizing basal dopamine transport and Tat-DAT integration. This study provides 
mechanistic insights into developing small molecules to block multiple sites in DAT for Tat binding.
About thirty-seven million people are currently living with HIV-1 infection worldwide, leading to a significant 
global public health problem. While the effective antiretroviral therapies significantly reduced the mortality rate 
in the patients with HIV-1 infection, nearly 50% of HIV-1 infected patients have various degrees of neurological 
complications that are referred to as HIV-1-associated neurocognitive disorders (HAND)1. The continuous expo-
sure of the central nerves system to HIV-1 viral proteins, inflammation, and antiretroviral agents results in neuro-
pathological and neurocognitive deficits observed in the patients with HAND2–7. Transactivator of transcription 
(Tat) protein, one of seven HIV-1 viral proteins, has been shown to play a critical role in HIV-1 viral replication as 
well as the development of HAND2,8, which can be exacerbated by concurrent cocaine abuse9. Thus, developing 
an intervention strategy in the early stage of HIV-1 infection would prevent the development of neurocognitive 
dysfunction in HIV-1 infected individuals.
Normal dopaminergic transmission is important for maintaining different brain activities including attention, 
learning, memory10,11, and motivation12,13. Dopamine (DA) transporter (DAT) is a presynaptic membrane protein 
that reuptakes the released DA from the synaptic cleft back into cytosol, maintaining a stable DA homeostasis. 
The DAT activity is directly inhibited by HIV-1 Tat protein and cocaine, which synergistically enhances synaptic 
DA levels9. The dysregulation of DA system is a mediating factor of HAND as well as a factor in cocaine abuse14,15. 
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Using computational modeling and experimental approach, we have identified several key residues on human 
DAT (hDAT), which are crucial for Tat-hDAT interaction and dynamic transport process9. Furthermore, we 
have demonstrated that in vitro exposure to Tat reduced reuptake of DA via hDAT in cells16–18 and rat striatal 
synaptosomes19. The inhibitory effect of Tat on DAT function results from Tat directly interacting with DAT16,20,21. 
Single point mutations of hDAT at tyrosine88 (to phenylalanine, Y88F), lysine 92 (to methionine, K92M), his-
tidine547 (to alanine, H547A) differentially alter basal DA uptake but attenuate the Tat inhibitory effects on DA 
transport17,18. For example, DA uptake is decreased in K92M and increased in H547A, respectively; however Y88F 
mutant preserves basal DA uptake17,18. Notably, the mutational effects on normal DA uptake and Tat inhibitory 
effect on DAT function are associated with alterations of transporter conformational transitions9.
We have demonstrated that Tat protein inhibits DAT function in an allosteric modulatory mechanism19,22. 
Recent studies have demonstrated that novel SRI-compounds exhibit a partial antagonistic role in DAT function 
as allosteric modulators23–25. We have reported that SRI-30827, one of the novel allosteric modulators, blocks Tat 
interaction with DAT26. Thus, identifying the specific binding sites on hDAT for Tat and its role in DA transport 
process could be beneficial to attenuation of the inhibitory effect of Tat on DAT-mediated dopaminergic trans-
mission. On the other hand, through an allosteric modulatory mechanism, the inhibitory effect of Tat on DAT 
function can also be diminished by targeting the specific DAT residues that are distinct from Tat binding sites. 
However, based on our computational structural models for Tat binding with hDAT, the interaction of Tat with 
hDAT involves multiple residues of DAT9,21 and our previous results obtained from single point mutations of 
DAT only present the role of a particular residue in Tat-DAT interaction. Therefore, this study investigated the 
mutational effects of Y88F/H547A and Y88F/K92M/H547A on basal DAT function, Tat inhibitory effect on DA 
uptake, and dynamic DA transport process.
Results
Computational modeling: Impact of Tyr88/His547 and Tyr88/Lys92/His547 on functional rele-
vance of human DAT. Based on the constructed hDAT-Tat binding model in our previous work20, hDAT 
residues Y88, K92, and H547 could form hydrogen bonds with residues K19, P18, and R49 of HIV-1 Tat, respec-
tively. According to our previous computational and experimental results, single mutation of either hDAT Y88 
(Y88F), K92 (K92M) or H547 (H547A) could significantly attenuate the binding between DAT and Tat17,18. As 
shown in Fig. 1A,B, hDAT Y88, K92 and H547 residues independently interact with Tat, suggesting an effect for 
double or triple mutation on disturbing DAT-Tat binding. For example, two hydrogen bonds in the DAT-Tat 
interface were eliminated by double mutation of Y88F/H547A on hDAT (Fig. 1C), and three hydrogen bonds in 
the DAT-Tat interface were eliminated by triple mutation of Y88F/K92M/H547A on hDAT (Fig. 1D). Therefore, 
one may expect that Y88F/H547A and Y88F/K92M/H547A mutants are more effective in inhibiting DAT-Tat 
binding than single point mutations of Y88F, K92M and H547A.
Mutations of Y88/H547 and Y88/K92/H547 differentially alter DA uptake kinetics and DAT binding. 
We have demonstrated that single point mutations on hDAT at His547 (H547A) and Lys92 (K92M) displayed 
a 196% increase and a 71% decrease in the Vmax of [3H]DA uptake, respectively, while Y88F preserved normal 
DA uptake17,18. The current study determined the multiple mutations of these residues on DA uptake and DAT 
binding sites. As shown in Table 1 and Fig. 2A, compared to WT hDAT (12.52 ± 0.68 pmol/min/105 cells), the 
Vmax values were increased by 92% in Y88F/H547A (24.06 ± 4.32 pmol/min/105 cells, t(7) = 2.33, p < 0.05) and 
dramatically decreased in Y88F/H547A/K92M (0.5 ± 0.31 pmol/min/105 cells, t(6) = 16.2, p < 0.001), respectively. 
Additionally, compared to WT hDAT (1.21 ± 0.17 µM), the Km value in Y88F/H547A was increased by 250% 
(4.25 ± 1.05 µM, t(7) = 2.54, p < 0.05) but not altered in Y88F/K92F/H547A.
In the hDAT, the [3H]WIN35,428 binding sites share pharmacological identity with the DA uptake site and 
is also part of the cocaine binding domain27,28. Kinetic analysis of [3H]WIN35,428 binding was conducted to 
determine the effects of multiple mutations of hDAT on the DA binding site. As shown in Table 2 and Fig. 2B, in 
comparison to WT hDAT, neither Bmax nor Kd values of [3H]WIN35,428 were altered in Y88F/H547A, whereas 
Y88F/K92M/H547A displayed a 61% decrease in the Bmax value (t(14) = 2.4, p < 0.05) and a 199% increase in the 
Kd value (t(14) = 4.4, p < 0.001). Thus, due to the significant reduction on DA uptake for Y88F/K92M/H547A, only 
the Y88F/H547A mutant was included for the rest of experiments.
Mutation of Y88/H547 alters the inhibition potency of DA uptake and DAT binding by sub-
strates and inhibitors. To characterize the influence of Y88F/H547A on DA transport and the specific 
binding site in hDAT for DA, cocaine, GBR12909, and amphetamine (AMPH), we determined the ability of 
these DAT inhibitors or substrate to inhibit [3H] DA uptake in WT hDAT and Y88F/H547A (Table 1). In com-
parison to WT hDAT, Y88F/H547A reduced the apparent affinity (IC50) for DA [WT hDAT: 2063 ± 582.5 nM; 
Y88F/H547A: 7918 ± 637.6 nM; t(10) = 6.78, p < 0.0001]. In contrast, compared to WT hDAT, Y88F/ H547A 
displayed an increase in IC50 for cocaine [WT hDAT: 350 ± 49.4 nM; H547A/Y88F: 131 ± 13.9 nM; t(6) = 4.28, 
p < 0.01] and GBR12909 [WT hDAT: 511 ± 56.6 nM; Y88F/H547A: 253 ± 40.4 nM; t(8) = 3.71, p < 0.01]. We also 
evaluated the mutational effect of Y88F/H547A on the IC50 of DA, cocaine, and GBR12909 for inhibiting [3H]
WIN35,428 binding (Table 2). Compared to WT hDAT, Y88F/H547A increased the IC50 values for DA (WT 
hDAT: 2291 ± 487.3 nM; Y88F/H547A: 7236 ± 1825 nM) and cocaine (WT hDAT: 235 ± 53.3; Y88F/H547A: 
1494 ± 333.0 nM, t(12) = 3.73, p < 0.001]. No difference in IC50 GBR12909 inhibiting [3H]WIN35,428 binding was 
observed between WT hDAT and Y88F/H547A.
Effect of Y88F/H547A on basal PKC-mediated regulation of DAT function. The activation 
of PKC by phorbol 12-myristate 13-acetate (PMA), a PKC activator, decreases DA uptake through DAT29,30. 
We have demonstrated that the addition of 1 µM PMA produced a 40% and 60% decrease in the Vmax of DA 
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uptake in WT hDAT and H547A mutant, respectively, compared to the respective control, suggesting that 
H547A displays increased sensitivity to PMA-induced DAT phosphorylation18. In the current study, we also 
found that Y88F/H547A displayed increased the Vmax relative to WT hDAT. We then determined whether Y88F/
H547A-upregulated DA uptake is also mediated by alteration of sensitivity to PMA-induced DAT phosphoryla-
tion (Fig. 3). A two way ANOVA analysis on the Vmax values of [3H]DA uptake revealed a significant main effect of 
PMA [F(1, 20) = 9.40, p < 0.01]. No significant mutation × PMA treatment interaction [F(1, 20) = 2.62; p = 0.076] was 
found. Addition of PMA reduced the Vmax values in WT hDAT by 51% [t(5) = 2.79, p < 0.05] and Y88F/H547A by 
60% [t(5) = 3.90, p < 0.05], respectively, compared to their respective vehicle controls. Similarly, two-way ANOVA 
analysis on the Km values revealed significant main effects of mutation [F(1, 20) = 5.52, p < 0.05] and PMA treat-
ment [F(1, 20) = 10.71, p < 0.001]. No significant interaction of mutation × PMA treatment was observed. The 
addition of 1 µM PMA reduced Km values by 53% in WT hDAT [t(5) = 3.31, p < 0.05] and 63% in Y88F/H547A 
[t(5) = 2.54, p < 0.05], respectively. These results suggest that the double mutation of Tyr88 and His547 attenuates 
the single mutant H547A-increased sensitivity of PMA-induced decrease in DA uptake.
Figure 1. Key residues, D-Y88, D-K92 and D-H547 involved in the HIV-1 Tat-DAT binding. (A) Typical Tat-
DAT binding complex from MD trajectory. Tat and DAT are represented as gold and cyan ribbons, respectively. 
The dashed box indicates the binding surface between Tat and DAT. (B) Tat residues, T-P18, T-K19 and 
T-R49, are represented as ball-stick style and colored in yellow. DAT residues, D-Y88, D-K92 and D-H547, are 
represented as ball-stick style and colored in green. Dashed lines represent inter-molecular hydrogen bonds 
with labeled distances. (The prefix T- and D- indicates residues of Tat and DAT, respectively). (C) Double 
mutation D-Y88F/D-H547A on hDAT-TAT structure. D-H547A mutation eliminates one hydrogen bond 
with T-R49, and D-Y88F mutation eliminates the hydrogen bond with T-K19. (D) Triple mutation D-Y88F/D-
K92M/D-H547A on hDAT-TAT structure. Addition of a triple mutation of D-Y88F, D-K92M, and D-H547A, 
also eliminates the hydrogen bond with T-P18.
Vmax (pmol/
min/105 cells) Km (µM)
IC50 (nM)
DA Cocaine GBR12909 AMPH
WT hDAT 12.52 ± 0.68 1.21 ± 0.17 2063 ± 582.5 350 ± 49.4 511 ± 56.6 926 ± 167.4
Y88F/H547A 24.06 ± 4.32* 4.25 ± 1.05* 7918 ± 637.6* 131 ± 13.9* 253 ± 40.4* 1279 ± 200.5
Y88F/ K92M/H547A 0.5 ± 0.31* 1.89 ± 1.25 ND ND ND ND
Table 1. Kinetic properties and inhibitory activities in [3H]DA uptake in WT and mutated hDAT. Data are 
presented as mean ± S.E.M. values from four to six independent experiments performed in duplicates. *p < 0.05 
compared with WT hDAT (unpaired Student’s t test). ND. Not determined.
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Double Mutation of H547/Y88 attenuate Tat-induced inhibition of DAT. Our previous studies 
demonstrated that single point mutation of Tyr88 (Y88F) or His547 (H547A) attenuated Tat-induced inhibition of 
[3H]DA uptake observed in WT hDAT17,18. Since the triple mutant (Y88F/K92M/H547A) displayed an extremely 
low Vmax of [3H]DA uptake, only the double mutant (Y88F/H547A) was tested for its effect on Tat-induced inhi-
bition of DA uptake. Based on the computational modeling predictions (Fig. 1), the double mutation of Tyr88 
and His547 would eliminate two pairs of hydrogen bonds between D-Y88-T-K19 and D-H547-T-R49 and impair 
Tat binding on hDAT, thereby attenuating Tat-induced inhibition of DA uptake. Due to the difference in the spe-
cific [3H]DA uptake between WT hDAT and Y88F/H547A mutants (Fig. 2), the inhibitory effects of Tat on DAT 
function in WT and Y88F/H547A were presented as % of Tat-mediated [3H]DA uptake relative to their respective 
Figure 2. Effects of Y88F/H547A and Y88F/K92M/H547A on [3H]DA uptake and [3H]WIN35,428 binding. 
(A) Kinetic parameters (Vmax and Km) of [3H]DA uptake in WT hDAT and mutants. [3H]DA uptake assay 
was conducted in PC12 cells transfected with WT hDAT and mutants by incubation with one of 6 mixed 
concentrations of the [3H]DA as the total rate of DA uptake. Nonspecific uptake of [3H]DA was determined by 
a parallel incubation of each mixed DA concentrations with nomifensine (10 µM, final concentration). Specific 
[3H]DA uptake (Vmax) was calculated by subtraction of nonspecific DA uptake from total DA uptake. The 
parameter values were presented as means ± S.E.M. *p < 0.05 compared to WT hDAT value (unpaired Student’s 
t test) (n = 4–5/group). (B) Saturation analysis of [3H]WIN35,428 binding in WT hDAT and mutants. Bmax and 
Kd values were estimated by fitting one-site binding and presented as means ± S.E.M. *p < 0.05 compared to 





WT hDAT 5.02 ± 0.71 9.27 ± 1.32 2291 ± 487.3 235 ± 53.3 485 ± 49.4
Y88F/H547A 3.16 ± 0.78 7.10 ± 0.74 7236 ± 1825* 1494 ± 333.0* 452 ± 113.0
Y88F/K92M/H547A 1.96 ± 0.39* 27.74 ± 6.50* ND ND ND
Table 2. Kinetic properties and inhibitory activities in [3H]WIN 35,428 binding in WT and mutated hDAT. 
Data are presented as mean ± S.E.M. of IC50 values from 4–12 independent experiments performed in 
duplicates. *p < 0.05 compared with WT hDAT (unpaired student’s t test). ND. Not determined.
5Scientific RepoRts |          (2019) 9:3843  | https://doi.org/10.1038/s41598-019-39872-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
controls (in the absence of Tat). As shown in Fig. 4, the application of 140 nM recombinant Tat1–86 (rTat1–86) sig-
nificantly reduced the specific [3H] DA uptake in WT hDAT by 31% relative to its control [t(4) = 11.54, p < 0.001]. 
However, the Tat-induced reduction of [3H] DA uptake in WT hDAT was attenuated in Y88F/H547A compared 
to its control [t(4) = 0.42, p > 0.05], suggesting that the double mutation of Tyr88 and His547 attenuates Tat’s 
inhibitory effect on DA uptake.
Effects of double mutation of Y88/H547 on zinc regulation of DAT conformational transitions 
and basal DA efflux. Tat protein has been shown to regulate DA transport allosterically, which may lead to 
alteration of transporter conformational transitions19,22. We have previously demonstrated that His547 residue 
Figure 3. Effects of PMA on basal PKC-regulated DAT function in WT hDAT and Y88F/H547A mutant. 
Kinetic analysis of [3H]DA uptake was conducted in the presence or absence of PMA (PKC activator, 1 µM). (A) 
Vmax and (B) Km. Data were presented as means ± S.E.M. (n = 6/group). *p < 0.05 compared to their respective 
controls (paired t-test after two-way ANOVA analyses).
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plays a critical role in allosteric modulation of Tat-DAT interaction18. To determine whether the His547 residue 
still acts as a potential site for the regulation of Tat-DAT in Y88F/H547A, we examined the effects of Y88F/
H547A on zinc modulation of [3H]DA uptake and [3H]WIN35,428 binding. Addition of Zn2+ is able to par-
tially reverse an inward-facing state to an outward-facing state31,32. On the basis of this principle, the addition 
of Zn2+ to WT hDAT would inhibit DA uptake, whereas in a functional mutation of DAT, Zn2+ might diminish 
the preference for the inward-facing conformation and thus enhance DA uptake. As shown in Fig. 5A, two-way 
ANOVA analysis on the specific [3H]DA uptake in WT hDAT and Y88F/H547A revealed significant main 
effects of mutation [F(1, 12) = 55.34, p < 0.0001], zinc [F(3, 36) = 39.15, p < 0.0001], and mutation × zinc interaction 
[F(3, 36) = 3.70, p < 0.05]. The addition of zinc significantly decreased the [3H]DA uptake in WT hDAT and its 
mutant in a concentration dependent manner. Compared to the respective controls (in absence of Zn2+), the 
addition of Zn2+ (10 and 100 µM) produced a similar reduction of [3H]DA uptake in WT (~40%, ps < 0.01) but a 
greater reductions (60% and 71% at 10 and 100 µM, respectively) in Y88F/H547A (ps < 0.01). This suggests that 
the double mutation of Y88/H547 does not affect zinc-induced regulation of DA uptake. In contrast, as shown 
in Fig. 5B, two-way ANOVA analysis of the specific [3H]WIN35,428 binding revealed significant main effects of 
mutation [F(1, 16) = 5.82, p < 0.05], zinc [F(3, 48) = 13.50, p < 0.0001], and mutation × zinc interaction [F(3, 48) = 9.94, 
p < 0.0001]. Compared to the respective controls (in absence of Zn2+), addition of Zn2+ (10 and 100 µM) signifi-
cantly increased [3H] WIN35,428 binding in WT hDAT (49% at 10 µM and 69% at 100 µM, ps < 0.05, Bonferroni 
t-test). The Zn2+ (10 and 100 µM)-induced increase in [3H]WIN 35,428 binding in WT hDAT was significantly 
diminished in Y88F/H547A [1 µM, t(16) = 2.37, p < 0.05; 10 µM, t(16) = 3.23, p < 0.01; 100 µM, t(16) = 3.57, p < 0.01], 
suggesting that Y88F/H547A attenuates zinc-induced increase in [3H]WIN35,428 of hDAT by altering trans-
porter conformational transitions.
To further determine the effect of Tyr88/His547 mutation on transporter conformational transitions, we 
examined basal efflux levels of [3H]DA in PC12 cells expressing WT hDAT and Y88F/H547A (Fig. 5C). twenty 
min after preloading with 0.05 µM [3H]DA, cells were washed and fractional DA efflux samples were collected at 
the indicated time. Two-way ANOVA revealed significant main effects of mutation [F(1, 8) = 59.38, p < 0.0001], 
time [F(5, 40) = 116.35, p < 0.0001], and mutation × time interaction [F(5, 40) = 8.16, p < 0.0001]. Post hoc analyses 
showed that compared to WT hDAT, DA efflux levels were significantly elevated at 1 and 10 min (ps < 0.05, 
Bonferroni t test).
Effects of Y88/H547 mutation on amphetamine-regulated DA efflux and uptake. AMPH acts as 
a substrate for DAT which subsequently reverses the transporter leading to DA efflux33,34. AMPH-stimulated [3H] 
DA efflux in PC12 cells transfected with WT hDAT and its mutants was determined under a stable baseline of DA 
efflux (Fig. 6A), showing no difference on basal [3H]DA efflux in control groups (F(4, 27) = 1.92, p = 0.14, one-way 
ANOVA). As shown in Fig. 6B, AMPH induced [3H]DA efflux in WT hDAT and mutants in a concentration 
dependent manner. Two-way ANOVA analysis on the Vmax values revealed significant main effects of mutation 
[F(4, 26) = 4.63, p < 0.01], AMPH [F(5, 130) = 76.81, p < 0.0001] and mutation × AMPH interaction [F(20, 130) = 2.34, 
p < 0.01]. As shown in Table 3, the Vmax values of [3H]DA efflux in response to AMPH were reduced in H547A 
(0.22 ± 0.04) and Y88F/H547A (0.20 ± 0.03) compared to WT hDAT (0.42 ± 0.03, ps < 0.05, Bonferroni’s multi-
ple comparison test). No difference in Km was found among WT hDAT and all mutants.
Double mutation of Tyr88 and His547 could induce DAT conformational change by altering AMPH inter-
action with DAT. We first examined the affinity for AMPH to inhibit [3H]DA uptake in WT and Y88F/H547A 
(Table 1), however, no significant difference in the IC50 value was found between WT (926 ± 167.4 nM) and Y88F/
H547A [1279 ± 200.5 nM, t(8) = 1.32, p = 0.22]. Next, we performed the kinetic analysis of [3H]DA uptake in WT 
Figure 4. Effects of Tat on kinetic analysis of [3H]DA uptake. PC12 cells transfected with WT hDAT or  
Y88F/H547A were preincubated with vehicle or recombinant Tat1–86 (rTat1–86) at room temperature for 20 min 
followed by [3H]DA application. Data were calculated as mean ± S.E.M. of specific [3H]DA uptake relative to 
respective controls as 100% for individual experiment (WT hDAT: 1109.30 ± 230.27 dpm and Y88F/H547A: 
400.13 ± 81.75 dpm and n = 5/group). *p < 0.05 compared to their respective controls (paired t test).
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Figure 5. Effects of Y88F/H547A mutant on transporter conformational transitions. (A) [3H]DA uptake and 
(B) [3H]WIN 35,428 binding were conducted in PC12 cells transfected with WT hDAT or Y88F/H547A which 
were incubated with one of the concentrations of ZnCl2 (1, 10, 100 µM, final concentration) or KRH buffer 
(control) followed by addition of a fixed concentration of [3H]DA uptake or [3H]WIN 35,428 binding. The 
histogram shows [3H]DA uptake and [3H]WIN 35,428 binding expressed as mean ± S.E.M. of the respective 
controls set as 100% for individual experiment. *p < 0.05 compared to the respective controls (Bonferroni t-
test) in [3H]DA uptake (n = 7/group) and [3H]WIN 35,428 binding (n = 9/group). #p < 0.05 compared to WT 
hDAT with same concentration of ZnCl2 application (unpaired student t-test). (C) DAT-mediated basal DA 
efflux properties of WT hDAT and mutant. Functional DA efflux was conducted in PC12 cells transfected WT 
hDAT or Y88F/H547A by preloading with a fixed concentration of [3H]DA (0.05 μM, final concentration) at 
room temperature for 20 min followed by replacing with fresh buffer at indicated time points. Finally, the buffer 
in each well was separated from cells, and radioactivity in the buffer and remaining in the cells was counted. 
Each fractional efflux value of [3H]DA in WT hDAT and Y88F/H547A was expressed as percentage of total 
[3H]DA in the cells at the start of the experiment. Fractional efflux values of [3H]DA at 1, 10, 20, 30 and 40 min 
are expressed as the percentage of total [3H]DA with preloading with 0.05 μM (WT hDAT: 11044 ± 241 dpm 
and Y88F/H547A: 660 ± 123 dpm) present in the cells at the start of the experiment (n = 5/group). ×p < 0.05 
compared to WT hDAT (Bonferroni t-test).
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Figure 6. Effects of AMPH on the kinetic analysis of DA efflux and uptake. PC12 cells transfected with WT 
hDAT and its mutants were washed, and preloaded with KRH buffer containing 50 nM [3H]DA for 20 min at 
room temperature. After three quick washes with KRH, aliquots from each well were collected and replaced 
with fresh KRH every 5 min for 15 min to establish basal efflux. At 20 min, AMPH (5–250 µM) was added, 
and the same aliquots were taken after 5 min as described in Material and Methods. (A) Baseline of [3H]DA 
efflux before addition of AMPH. Data were presented as means ± S.E.M. of the ratios of efflux to [3H]DA in 
cells (efflux dmp/cellular dmp) in WT hDAT and mutants (n = 4–13). (B) AMPH-mediated efflux is expressed 
as means ± S.E.M. of the fractional release of cellular [3H]DA per 5 min in WT and mutants. (C,D) kinetic 
analysis of [3H]DA uptake in WT hDAT and Y88F/H547A in the presence or absence of AMPH (1 µM). Data 
were presented as means ± S.E.M. (n = 5/group). *p < 0.05 compared to their respective controls (paired t test) 
#p < 0.05 compared to WT hDAT value (unpaired Student’s t test).
WT hDAT Y88F Y88A H547A Y88F/H547A
Vmax 0.42 ± 0.03 0.28 ± 0.06 0.29 ± 0.01 0.22 ± 0.04** 0.20 ± 0.03**
Km 10.2 ± 3.2 7.61 ± 2.00 9.80 ± 5.11 9.49 ± 6.52 9.31 ± 4.7
Table 3. Kinetic analysis of AMPH-stimulated [3H]DA efflux in WT hDAT and mutants. Data are presented as 
mean ± S.E.M. of the Vmax and Km values for AMPH-stimulated [3H]DA in WT hDAT and its mutants from 5–13 
independent experiments. *p < 0.05 compared to WT hDAT values (Bonferroni’s multiple comparison test).
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and Y88F/H547A in presence of AMPH (1 µM, final concentration). As shown in Fig. 6C, two-way ANOVA anal-
ysis on the Vmax of [3H]DA uptake reveled significant main effects of mutation (F(1, 16) = 9.50, p < 0.01) and AMPH 
(F(1, 16) = 11.99, p < 0.01). No significant interaction of mutation × AMPH treatment was found (F(1, 16) = 1.61, 
p = 0.22). Post hoc analyses show that the Vmax value in Y88F/H547A (18.9 ± 2.81 pmol/min/105 cells) was higher 
than that in WT hDAT (11.5 ± 0.94 pmol/min/105 cells, t(8) = 2.49, p < 0.05, n = 5/group) in the absence of 
AMPH. AMPH decreased the Vmax in both WT hDAT (32%, 7.80 ± 0.97 pmol/min/105 cells, t(8) = 2.76, p < 0.01) 
and Y88F/H547A (42%, 10.9 ± 1.33 pmol/min/105 cells, t(8) = 2.58, p < 0.05) compared with their respective con-
trols. There was a significant difference in the magnitude of the AMPH-induced decrease in Vmax values between 
WT hDAT and Y88F/H547A (t(8) = 1.86, p < 0.05). Furthermore, two-way ANOVA analysis on Km values revealed 
significant main effects of mutation [F(1, 16) = 21.06, p < 0.001] and AMPH [F(1, 16) = 10.17, p < 0.01],whereas no 
significant interaction of mutation × AMPH treatment was found [F(1, 16) = 0.13, p = 0.73]. In the absence of 
AMPH, the Km values of [3H]DA uptake was greater in Y88F/H547A (5.12 ± 0.76 µM) than that in WT hDAT 
[1.43 ± 0.15 µM, t(8) = 4.79, p < 0.01). Compared to the controls, AMPH significantly increased the Km value in 
WT hDAT [4.08 ± 0.56 µM; t(8) = 4.63, p < 0.01], which was attenuated in Y88F/H547A (7.24 ± 1.15 µM).
Discussion
Our recent studies demonstrated that single hDAT mutants, Y88F, K92M, and H547A differentially regulate DAT 
reuptake but attenuate Tat’s inhibitory effect on DAT function. This study sought to determine whether multiple 
mutations on these hDAT residues (Y88F/H547A) and (Y88F/K92M/H547A) influence the direct interactions 
between Tat and DAT. There were three major findings. First, compared with WT hDAT, Y88F/H547A enhances 
Vmax of DA uptake, whereas Y88F/K92M/H547A dramatically reduces the Vmax. Second, consistent with the com-
putational modeling prediction, Y88F/H547A attenuates Tat-induced inhibition of DA uptake observed in WT 
hDAT. The third finding is that Y88F/H547A displays an attenuation of zinc ion modulation of [3H]WIN35,428 
binding, increased basal DAT-mediated DA efflux, and reduced AMPH-stimulated DA efflux. Collectively, 
these findings suggest that targeting DAT residues Tyr88 and His547 may have potential therapeutic benefits on 
Tat-induced dysregulation of dopaminergic system seen in patients with HAND.
According to our computationally modeled structures, Y548-Y470-Y551 is a stable motif (denoted as the 
YYY motif for convenience) essential for the conformational conversion of hDAT required for the DA transport 
process35. This YYY motif has hydrophobic contact with a typical U-turn loop associated with extracellular loop 6 
(EL6) and transmembrane 10 (TM10a). Any structural changes affecting the stability of the YYY motif could dest-
abilize the R85-D476 salt bridge of hDAT, and the salt bridge is key for the conformational conversion36–39. H547 
is expected to significantly affect the hDAT stability because H547 is adjacent to Y548 of the YYY motif35, which 
is consistent with the observed increase in DA uptake by the H547A mutation18. On the other hand, the side chain 
of K92 residue (TM1b) forms a favorable salt bridge with the side chain of D313 (TM6a) during the molecular 
dynamics simulation on the hDAT-DA binding complex, and the bridge is also essential for the conformational 
conversion of hDAT required for the DA uptake process40. For this reason, disrupting the K92-D313 salt bridge 
will likely impair or slow down the DA uptake process, which has been validated pharmacologically by mutations 
on K92 (K92M)17 and D313 (D313N)41. In addition, the aromatic ring on the side chain of Y88 is sandwiched by 
TM1b and extracellular loop 4 (EL4) in a hydrophobic region of hDAT. Therefore, mutation of Y88 to phenyla-
lanine retains the normal reuptake function of hDAT and demonstrated no difference compared to WT hDAT17. 
However, Y88F increased the Km of DA binding by about 50%, suggesting that Y88F may slightly alter the local 
structure around Y8817. In the current study, the double mutant Y88F/H547A retains the increased Vmax observed 
in H547A, suggesting a critical role of the mutated H547 residue in regulating transporter activity. In contrast, 
the combination of the mutated residues Y88, K92, and H547 does not follow a simple math addition, because 
compared to WT hDAT, a 96% reduction of Vmax was observed in Y88F/K92M/H547A, whereas the Vmax was 
decreased by 71% in K92M17. These results suggest that the inclusion of the K92 mutation in the K92-D313 salt 
bridge is a critical factor in the differential DAT kinetics in the triple mutation of hDAT. As Y88 is spatially adja-
cent to R85 and K92 in helix TM1b, the double mutations on both Y88F and K92M are expected to induce more 
structural disturbance to the R85-D476 and K92-D313 salt brides, thus further decreasing Vmax of the transporter. 
Therefore, triple mutant Y88F/K92M/H547A has a lower Vmax compared to, single mutant K92M. Although 
including K92M mutation significantly decreases the Vmax for DA uptake in the triple mutant Y88F/K92M/
H547A compared to Y88F/H547A, no significant change in the Bmax of [3H]WIN 35,428 binding is found in the 
double or triple mutants, suggesting that the multiple mutations may alter DAT re-uptake function rather than 
the substrate binding sites on DAT. This conclusion is also supported by the increased Km in Y88F/H547A and 
no change in Km in Y88F/K92M/H547A. However, single point mutations of Y88, K92, and H547 differentially 
affect the Vmax with no changes in the Km17,18. One possible explanation is that allosteric modulation of the 
dynamic DA transport process may be responsible for the enhanced Vmax and its associated DA uptake potency.
We further determined the effect of double mutant Y88F/H547A on the basal DA uptake via hDAT and bind-
ing potency for DA, GBR12909, and cocaine. Y88F/H547A had decreased the potency for [3H]DA to inhibit DA 
uptake relative to WT hDAT, which is similar to that in Y88F and H547A16,18. However, Y88F/H547A increased 
the DA uptake potency for cocaine and GBR12909, which is consistent with the single mutation of Y88F relative 
to WT hDAT17. Similar to Y88F17, Y88F/H547A displayed decreased potency for DA to inhibit [3H]WIN35,428 
binding. However, the inhibition potency of [3H]WIN35,428 binding for cocaine was decreased in Y88F/H547A 
but increased in Y88F17. Y88F/H547A, similar to Y88F17, retained the [3H]WIN35,428 binding potency for 
GBR12909. GBR12909 is a selective inhibitor of DA uptake, binding to the piperazine acceptor site without influ-
encing DA release42; while cocaine is a competitive inhibitor for DAT and prefers to an outward-facing transport 
state, leading to a decrease in DA transport43,44. According to our computational modeling prediction, both hDAT 
residues Y88 and H547 are the critical binding sites on DAT for Tat20. Therefore, our findings demonstrate that 
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through allosteric modulation, mutation of Y88 and H547 alters the inhibition potency for DA uptake and DAT 
binding site for substrate and DAT inhibitors40.
Our previous study has demonstrated that mutant H547A displays increased sensitivity to PKC-mediated 
downregulation of DAT function by PMA compared to WT hDAT18. Interestingly, the current study shows no 
difference in PMA-mediated reduction of DA uptake between Y88F/H547A and WT hDAT, indicating that Y88F/
H547A-induced increase in Vmax is independent of PKC activity. It has been shown that PKC-mediated phospho-
rylation of DAT downregulates DA uptake velocity45–47. Through allosteric modulatory effect, single mutation of 
H547 may alter the levels of PKC-induced phosphorylation of DAT activity, thereby causing the increased Vmax. 
However, double mutation of Y88 and H547 may attenuate the intermolecular structural interaction across PKC 
phosphorylation sites. Indeed, compared with WT hDAT, H547A, and Y88F/H547A enhances the Vmax values by 
196%18 and 96%, respectively. In addition to PKC-mediated regulation of DAT function, activation of palmitoyl 
acyltransferase, a group of enzymes that transfer palmityl group to -SH group on cysteine on a protein, enhances 
DA uptake via DAT palmitoylation48. Therefore, we will investigate whether Y88F/H547A-induced increased DA 
uptake is dependent on palmitoylation activity.
A major finding is that the double mutant Y88F/H547A completely attenuates the Tat-mediated inhibition of 
DAT reuptake function, which is consistent with our previous reports on Y88F- or H547A-induced attenuation 
of the Tat’s effect17,18. According to our computational modeling prediction, either the Y88 or H547 residue could 
form hydrogen bonds with Tat residue K19 or R49 independently, suggesting that the double mutation of Y88 
and H547 eliminated Tat-DAT binding. Hence, our pharmacological study further validates the computational 
prediction for the complementary hydrophobic interactions between Tat and hDAT. Furthermore, since we have 
demonstrated that Tat interacts with DAT allosterically19,22, the current findings also suggest that double muta-
tion of Y88 and H547 attenuates Tat effect through a conformational mechanism. First, Y88F/H547A attenuates 
zinc-mediated increase in [3H]WIN35,428 binding relative to WT hDAT. Second, Y88F/H547A augments basal 
DA efflux when compared to WT hDAT, which opposes our previous reports showing that neither Y88F nor 
H547A affected the basal efflux17,18. The elevated basal DA efflux in Y88F/H547A may be attributed to its elevated 
Vmax of DA uptake and DA accumulation. Taken together, Y88F/H547A, via an alteration of DAT conformational 
transitions, may influence the binding structure of hDAT-Tat complex, thereby disrupting Tat-induced inhibition 
of DA uptake. Studying the multiple mutation of DAT residues in Tat-DAT intermolecular interaction will greatly 
contribute to our ongoing proof of concept studies using novel allosteric modulators to establish their potential 
for therapeutic application in HAND.
AMPH, a substrate of DAT, competitively inhibits the reuptake of DA and elicits DAT-mediated DA efflux by 
reversal of the transporter49. Our computational modeling has demonstrated that the dynamic DA uptake process 
includes outward-open, outward-occluded, and inward-open states21, which can be reversed by DA substrate and 
DAT mutation49–51. The current results indicate that the potency for AMPH inhibition of [3H]DA uptake was 
not altered in Y88F/H547A compared with WT hDAT, suggesting that the mutation of Tyr88 and His547 does 
not alter the interaction of AMPH with hDAT. However, AMPH-mediated DA efflux was reduced in H547A and 
Y88F/H547A, suggesting that mutations of Tyr88 and His547 residues alter the conformational equilibrium of the 
DAT transport transitions. Furthermore, AMPH decreases the Vmax of DA uptake in both WT hDAT and Y88F/
H547A, which is consistent with the previous report51, however, the magnitude of the AMPH-mediated reduction 
of the Vmax in Y88F/H547A was greater than that in WT hDAT. Interestingly, the AMPH-mediated reduction of 
the Vmax was accompanied by increased Km values in WT hDAT but not Y88F/H547A. Given that DAT-mediated 
DA transport is accompanied by reuptake of two Na+ and Cl− ions, AMPH influx would transport Na+ through 
DAT and enhance its levels at the inner face of the transporter52. Therefore, AMPH decreases DA transport but 
increases Km values in WT hDAT, whereas altered transporter conformation by Y88F/H547A may attenuate the 
increased Km. Taken together, the results along with attenuated zinc-regulated [3H] WIN35,428 binding and 
increased basal DA efflux in Y88F/H547A further support that mutations of Tyr88 and His547 cause an alteration 
in conformational transitions, thereby disrupting the inhibitory effect of Tat on DAT reuptake function.
In conclusion, our data further demonstrate DAT Tyr88 and His547 as important residues for DAT func-
tion and the Tat-DAT interaction. Double mutation of these residues preserves single mutant H547A-mediated 
enhancement of DA uptake and diminishes Tat-induced inhibition of DA transport18. An allosteric modula-
tory mechanism may contribute to Y88F/H547A-mediated attenuation of Tat-induced inhibition of DA trans-
port. Understanding the multiple mutation effects of the identified DAT residues might provide a basis for a 
novel approach for developing compounds to attenuate Tat binding to DAT by an allosteric mechanism in HIV-
1-infected individuals.
Materials and Methods
Prediction of Tat-DAT binding model. We performed computational modeling and simulations to 
model the binding structure of hDAT with HIV-1 clade B type Tat based on the nuclear magnetic resonance 
(NMR) structures of Tat53 and the constructed structure of hDAT-DA complex21. Protein docking and molecular 
dynamics simulations were employed to identify the conformation of hDAT-Tat complex. The energy-minimized 
complex structure used in this work were extracted from long-time equilibrated molecular dynamics simulation 
trajectories in our previous work17,18,20,35.
Construction of plasmids. We selected the mutations of Y88, H547, Y88/H547 and Y88/K92/H547 based 
on predictions of computational modeling and simulations (Fig. 1) and our previous studies17,18. Single mutants, 
Y88F, K92M, and H547A, are expected to abolish hydrogen bonds between hDAT and Tat. Double (H547A/Y88F) 
and triple (H547A/Y88F/K92M) mutations were generated based on the wild type hDAT (WT hDAT) sequence 
(NCBI, cDNA clone MGC: 164608 IMAGE: 40146999) by site-directed mutagenesis. We then used the synthetic 
cDNA encoding hDAT subcloned into pcDNA3.1 + as a template to generate mutants using QuikChange™ 
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site-directed mutagenesis Kit (Agilent Tech, Santa Clara CA). We performed the DAT sequence for confirming 
the sequence of the mutant construct at University of South Carolina EnGenCore facility. Plasmids DNA were 
propagated and purified using a plasmid isolation kit (Qiagen, Valencia, CA, USA).
Cell culture and DNA transfection. In the current study, we used rat pheochromocytoma cells (PC12 
cells, CRL-1721, American Type Culture Collection (ATCC), Manassas, VA), which were maintained in 
Dulbecco’s modified eagle medium (DMEM, Life Technologies, Carlsbad, CA) supplemented with 15% horse 
serum, 2.5% bovine calf serum, 2 mM glutamine and antibiotics, 100 U/mL penicillin and 100 µg/mL streptomy-
cin. Cells were cultured at 37 °C in a 5% CO2 incubator. Once cells were growing to 100% confluence on plates, 
cells were seeded at a density of 1 × 105 cells/cm2 in 24-well plates and transfected with WT hDAT or mutants 
by Lipofectamine 2000 (Life Technologies). Twenty-four hours after transfection, intact cells or cell suspensions 
were used for experiments.
[3H]DA uptake assay. In order to determine whether DAT mutants alter DAT function, we evaluated the 
maximal velocity (Vmax) or Michaelis-Menten constant (Km) of [3H]DA uptake in intact PC12 cells transfected 
with WT hDAT or mutants as reported previously16,17. Twenty-four hours after transfection, cells in 24-well plates 
were washed twice with Krebs-Ringer-HEPES (KRH) buffer (final concentration in mM: 125 NaCl, 5 KCl, 1.5 
MgSO4, 1.25 CaCl2, 1.5 KH2PO4, 10 D-glucose, 25 HEPES, 0.1 EDTA, 0.1 pargyline, and 0.1 L-ascorbic acid; 
pH 7.4) and incubated with nomifensine (10 µM, final concentration) as nonspecific uptake for 10 min at room 
temperature. A fixed concentration of [3H]DA (500,000 dpm/well, specific activity, 21.2 Ci/mM; PerkinElmer Life 
and Analytical Sciences, Boston, MA) mixed with one of six concentrations of unlabeled DA (final DA concen-
trations, 0.03–5 µM) were applied to cells at room temperature for additional 8 min. The specific DAT-mediated 
DA uptake was calculated by subtracting non-specific uptake from total uptake (in the absence of nomifensine). 
The reaction was terminated by removal of solution from wells and quickly washed three times with ice cold KRH 
buffer. Cells were then lysed in 500 μL of 1% SDS for an hour and radioactivity was measured using a liquid scin-
tillation counter (Tri-Carb 2900TR; PerkinElmer Life and Analytical Sciences, Waltham, MA).
To confirm whether Y88F/H547A-induced increase in Vmax was dependent on PKC regulatory mechanism, 
the Vmax of [3H]DA uptake was measured in the presence or absence of 1 µM PMA, a PKC activator (Tocris, 
Bristol, UK) as the previous reports29,30. Intact PC12 cells transfected with WT or Y88F/H547A were preincu-
bated with or without PMA for 30 min at 37 °C followed by additional 8 min incubation with six concentrations of 
mixed [3H]DA as described above. To determine the effect of amphetamine (AMPH) on Y88F/H547A-mediated 
transporter conformational transitions, Vmax or Km of [3H]DA uptake in WT and Y88F/H547A was determined in 
the presence or absence of 1 µM AMPH (Sigma-Aldrich, St. Louis, MO) as reported previously51.
To determine whether these mutations alter the affinity of DAT substrate or inhibitors as well as 
Zn2+-regulation of DA transport, we performed the competitive inhibition of DA uptake in intact PC12 cells 
transfected with WT or mutant, which were preincubated with a series of final concentrations of DA (1 nM-1 
mM), GBR12909 (1 nM-10 µM), cocaine (1 nM-1 mM), AMPH (1 nM-1 mM) or ZnCl2 (1, 10, and 100 μM) at 
room temperature for 10 min followed by additional 8 min incubation with a fixed concentration of [3H]DA 
(0.05 µM, final concentration).
In order to determine whether double mutation of Y88 and H547 disrupts Tat and DAT interaction, we per-
formed the specific [3H]DA uptake in PC12 cells transfected with WT or mutant in the presence or absence of 
Tat protein. In brief, cells were dissociated with trypsin/EDTA (0.25%/0.1%, 1 mL for one 10 cm dish) and resus-
pended in culture medium and incubated at room temperature for 10 min. The dissociated cells were collected by 
centrifugation at 400 × g for 5 min at 4 °C and washed once with phosphate-buffered saline followed by additional 
5 min centrifugation (400 × g, 4 °C). Finally, the resulted cell pellets were resuspended in KRH assay buffer. The 
cell suspensions from WT hDAT or Y88F/H547A mutant were then preincubated with or without recombinant 
Tat1–86 (rTat1–86, 140 nM, final concentration, Diatheva, Fano, Italy) at room temperature for 20 min followed by 
additional 8 min incubation with a mixed [3H]DA uptake (0.05 µM, final concentration). Non-specific [3H]DA 
uptake was determined in the presence of 10 µM nomifensine. The update reaction was terminated by immediate 
filtration through Whatman GF/B glass filters (presoaked with 1 mM pyrocatechol for 3 h) followed by three 
washes with 3 mL of ice-cold KRH buffer containing pyrocatechol using a Brandel cell harvester (model M-48; 
Brandel Inc., Gaithersburg, MD). Radioactivity was determined as described above.
[3H]WIN 35,428 Binding Assay. Binding assays were used to determine the kinetic parameters (Bmax or Kd) 
of [3H]WIN 35,428 binding in intact PC12 cells transfected with WT hDAT or mutant. Cells were washed with 
sucrose-phosphate buffer twice (final concentration in mM: 2.1 NaH2PO4, 7.3 Na2HPO47H2O, and 320 sucrose, 
pH 7.4) and then incubated with one of the six concentrations of [3H]WIN 35,428 (84 Ci/mmol, PerkinElmer, 0.5–
30 nM final concentrations) in a final volume of 500 μL on ice for 2 h. Nonspecific binding at each concentration of 
[3H]WIN 35,428 was determined by adding in the presence of 30 µM cocaine (final concentration) and subtracted 
from total binding to obtain the specific binding. For competitive inhibition experiments, assays were performed 
in a final volume of 250 μL. Intact PC12 cells transfected with WT or mutated hDATs were incubated in buffer con-
taining 25 μL of [3H]WIN 35,428 (final concentration, 5 nM) and one of ten concentrations of DA (1 nM- 100 μM), 
cocaine (1 nM- 100 μM), GBR12909 (0.01 nM- 1 μM) or ZnCl2 (1, 10, 100 μM) on ice for 2 h. Assays were terminated 
by removing reaction reagents in each well followed by two washes with ice-cold assay buffer. Cells were lysed with 
1% SDS for an hour and subjected to the radioactivity measurement as described above.
[3H]DA efflux assay. Basal DA efflux was performed at room temperature as described previously16–18. Intact 
PC12 cells transfected with WT hDAT or its mutant were preloaded with 0.05 μM [3H]DA for 20 min and then 
washed 3 times with KRH buffer prior to collecting fractional efflux samples. To obtain an estimate of the total 
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amount of [3H]DA in the cells at the zero time point, cells from a set of wells (four wells/sample) were lysed rap-
idly in 1% SDS after preloading with [3H]DA. To collect factional efflux samples, buffer (500 μL) was added into a 
separate set of cell wells and transferred to scintillation vials after 1 min as an initial fractional efflux, and another 
500 μl buffer was added to the same wells and collected after 10 min as second fractional efflux. Additional frac-
tional efflux at 20, 30, 40, 50 min, respectively, was repeated under the same procedure. After last fractional efflux, 
cells were lysed and counted as total amount of [3H]DA remaining in the cells from each well.
To further determine DAT mutation-mediated transporter confirmation transitions, basal efflux and 
AMPH-stimulated DA efflux in WT hDAT and its mutants were measured as reported previously51. PC12 cells 
transfected with WT hDAT and its mutants growing in 24-well plates were preloaded with [3H]DA (50 nM, final 
concentration) for 20 min at room temperature. Subsequently, cells in all plate wells were washed with KRH for 
three times, cells were then incubated with KRH buffer containing AMPH (5–250 µM) or vehicle (KRH buffer 
alone, as baseline control) for 15 min at room temperature. After incubation, the buffer solution incubated with 
AMPH or vehicle was collected as AMPH-stimulated efflux or baseline efflux. Cells were lysed in 1% SDS and 
subject to count for obtaining the initial amount of DA (total DA) in the cells.
Data analysis. In the current study, all data are presented as mean ± SEM with n as the number of inde-
pendent experiments for each experiment group. Pharmacological parameter values (Vmax, Km, Bmax, and Kd) and 
IC50 from [3H]DA uptake and [3H]WIN 35,428 binding were calculated by nonlinear regression analysis using 
a one-site model with variable slope. To determine the significant difference in the pharmacological parameters 
between unpaired sample groups, such as WT hDAT and its mutants, unpaired Student’s t test was used for the 
statistical comparisons. Significant differences between sample groups were analyzed with separate ANOVAs 
followed by post-hoc, Bonferroni multiple comparison test as indicated in the results Section of each experiment. 
All statistical analyses were performed using IBM SPSS Statistics version 25, and differences were considered 
significant at p < 0.05.
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